ESMO 2022 Conference Coverage


 

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibition in Locally Advanced dMMR Colon Cancer

900 views
September 16, 2022
0 Comments
Login to view comments. Click here to Login
GI